Inici › Tumors cerebrals › Massachusetts › Boston
Assaigs clínics de Tumors cerebrals a Boston, MA
28 estudis de Tumors cerebrals busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
ReclutantFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ReclutantFase 1/2
- Tufts Medical Center, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
ReclutantFase 1/2
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutantFase 2
- Local Institution - 0124, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
Reclutant
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ReclutantFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
ReclutantFase 1/2
- Dana-Farber Cancer Institute, Boston
Targeted Pediatric High-Grade Glioma Therapy
ReclutantEstudi observacional
- Dana-Farber Cancer Institute, Boston
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
ReclutantFase 2
- Massachusetts General Hospital, Boston
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
ReclutantFase 2
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
ReclutantFase 2
- Brigham and Women's Hospital, Boston
B7-H3.CD28Z.CART in CNS Neoplasms
ReclutantFase 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
ReclutantFase 2
- Susan Chi, Boston
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
Reclutant
- Massachusetts General Hospital, Boston
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
ReclutantEstudi observacional
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Palbociclib and Pembrolizumab In Central Nervous System Metastases
ReclutantFase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
ReclutantFase 3
- Tufts Medical Center, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
ReclutantFase 2
- Dana-Farber Cancer Institute, Boston
NTS-WBRT in Brain Metastases
ReclutantFase 2
- Massachusetts General Hospital Cancer Center, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
ReclutantFase 1/2
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
Reclutant
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Reclutant
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
ReclutantFase 1 inicial
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
ReclutantFase 1/2
- Beth Israel Deaconess Medical Center, Boston
ASCENT Intervention for Brain Tumor Patients
Reclutant
- Massachusetts General Hospital Cancer Center, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
ReclutantEstudi observacional
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
ReclutantEstudi observacional
- Massachusetts General Hospital, Boston
Assaigs de Tumors cerebrals en altres ciutats
- Houston, TX35 estudis
- New York City, NY25 estudis
- Washington, DC20 estudis
- Los Angeles, CA16 estudis
- Miami, FL15 estudis
- Durham, NC14 estudis
- St. Louis, MO12 estudis
- Cleveland, OH11 estudis
- Seattle, WA11 estudis
- Rochester, MN11 estudis
- Baltimore, MD11 estudis
- Columbus, OH11 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Càncer de pròstata59 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.